Novo Nordisk A/S (TSX:NOVO)
Canada flag Canada · Delayed Price · Currency is CAD
19.66
-1.29 (-6.16%)
At close: Feb 4, 2026

Revenue

Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Rybelsus Revenue
22.09B
Ozempic Revenue
127.09B
Victoza Revenue
3.02B
Total GLP-1 Revenue
152.20B
Long-Acting Insulin Revenue
18.76B
Premix Insulin Revenue
10.32B
Fast-Acting Insulin Revenue
18.58B
Human Insulin Revenue
5.48B
Total Insulin Revenue
53.14B
Other Diabetes Care Revenue
1.77B
Total Diabetes Care Revenue
207.11B
Wegovy Revenue
79.11B
Saxenda Revenue
3.24B
Total Obesity Care Revenue
82.35B
Diabetes & Obesity Care Revenue
289.46B
Rare Blood Disorders Revenue
11.96B
Rare Endocrine Disorders Revenue
5.96B
Other Rare Disease Revenue
1.69B
Rare Disease Revenue
19.61B
Revenue (Total)
309.06B

Revenue by Geography

Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
US Revenue
173.17B
EUCAN Revenue
66.09B
Emerging Markets Revenue
30.44B
APAC Revenue
20.71B
China Revenue
18.66B
Total International Revenue
135.90B
Revenue (Other)
-135.90B
Revenue (Total)
309.06B

Revenue by Geography 2

Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
US Revenue (Pre-FY2024 Reporting)
173.17B
China Revenue (Pre-FY2024 Reporting)
18.66B
Revenue (Total)
309.06B

EBIT

Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Diabetes & Obesity Care Operating Profit
126.45B
Rare Disease Operating Profit
1.21B
Operating Income (Total)
127.66B
Updated Dec 31, 2025. Data Source: Fiscal.ai.